Immutep Ltd Sponsored ADR Stock

$1.64

0.61% yesterday

Nasdaq, Jun 27, 10:00 pm CET

ISIN

US45257L1089

Symbol

IMMP

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Immutep Ltd Sponsored ADR Stock price

$1.64

+0.54 49.09% 5Y

Nasdaq, Closing price Fri, Jun 27 2025

+0.01 0.61%

ISIN

US45257L1089

Symbol

IMMP

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Basic

Market capitalization

$233.7m

Enterprise Value

$130.8m

Net debt

$-102.9m

Cash

$104.0m

Shares outstanding

1.5b

Valuation (TTM | estimate)

P/E

negative | negative

P/S

5,842.80 | 61.93

EV/Sales

3,269.55 | 34.66

EV/FCF

negative

P/B

21.19

Financial Health

Equity Ratio

94.02%

Return on Equity

-22.54%

ROCE

-31.66%

ROIC

-347.90%

Debt/Equity

0.01

Financials (TTM | estimate)

Revenue

$40.0k | $3.8m

EBITDA

- | $-39.0m

EBIT

$-35.8m

Net Income

$-28.7m | $-41.7m

Free Cash Flow

$-30.3m

Growth (TTM | estimate)

Revenue

-76.47% | 4,616.88%

EBITDA

- | -

EBIT

-16.08%

Net Income

-9.02% | -49.57%

Free Cash Flow

-10.06%

Margin (TTM | estimate)

Gross

EBITDA

- | -1,033.36%

EBIT

-101,680.71%

Net

-81,383.86% | -1,105.73%

Free Cash Flow

-86,060.85%

EPS

$-0.02

FCF per Share

$-0.02

Short interest

2.93%

Employees

31.00

Rev per Employee

$0.00

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Get Started for Free Today

Immutep Ltd Sponsored ADR Stock Analysis

Unlock Scores for Free

??

9 Analysts have issued a Immutep Ltd Sponsored ADR forecast:

8x Buy

89%

More details on Analyst Estimates Including Price Targets

9 Analysts have issued a Immutep Ltd Sponsored ADR forecast:

Buy

89%

Hold

11%

Analyst Estimates with Stock Price Targets

Financial data from Immutep Ltd Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Dec '24		+/- %
Revenue	0.04 0.04	76% 76% 100%
- Direct Costs	- -	- -
Gross Profit	- -	- -
- Selling and Administrative Expenses	5.41 5.41	11% 11% 13,525%
- Research and Development Expense	30 30	23% 23% 75,850%
EBITDA	- -	- -
- Depreciation and Amortization	- -	- -
EBIT (Operating Income) EBIT	-36 -36	16% 16% -89,498%
Net Profit	-29 -29	9% 9% -71,625%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Immutep Ltd Sponsored ADR Stock News

Neutral

GlobeNewsWire

●

about one month ago

Immutep's Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma

SYDNEY, AUSTRALIA, May 27, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces the investigator-initiated EFTISARC-NEO Phase II trial evaluating eftilagimod alfa (efti) with radiotherapy plus KEYTRUDA® (pembrolizumab) in the neoadjuvant setting for resectable ...

Positive

Seeking Alpha

●

about 2 months ago

Immutep Limited: Surging On Positive Head And Neck Data

Immutep's eftilagimod shows promising results in head and neck cancer, with a median overall survival of 17.6 months, significantly higher than what has been observed with other approaches. IMMP is well-capitalized with $146.3 million in liquidity, ensuring operations can continue without imminent dilution and funding issues. Despite promising phase 2 data, the fate of eftilagimod remains uncer...

Neutral

GlobeNewsWire

●

3 months ago

Immutep to Participate in Upcoming Investor Conferences

SYDNEY, AUSTRALIA , April 02, 2025 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces its management will present and participate in one-on-one meetings at the following investor conferences:

More Immutep Ltd Sponsored ADR News

Company Profile

Immutep Ltd. is a biotechnology company, which engages in the research and development of immunotherapeutic treatments for cancer and autoimmune diseases. Its product is IMP321, which involves in clinical development for the treatment of breast cancer and melanoma. The company was founded on May 21, 1987 and is headquartered in Sydney, Australia.

Head office	Australia
CEO	Marc Voigt
Employees	31
Founded	1987
Website	www.immutep.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now